IONIS-AR-2.5Rx / Ionis, Suzhou Ribo, Flamingo Therapeutics - LARVOL DELTA

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: University of Michigan Rogel Cancer Center | Phase classification: P1/2 ➔ P1

Combination therapy • Metastases • Phase classification • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=9 | Terminated | Sponsor: University of Michigan Rogel Cancer Center | Trial completion date: Jan 2022 ➔ Jan 2023 | Trial primary completion date: Jan 2022 ➔ Jan 2023

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=9 | Terminated | Sponsor: University of Michigan Rogel Cancer Center | N=35 ➔ 9 | Suspended ➔ Terminated; Cancelled by the sponsor

Combination therapy • Enrollment change • Metastases • Trial termination • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=35; Recruiting; Sponsor: University of Michigan Rogel Cancer Center; Suspended ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=35; Suspended; Sponsor: University of Michigan Rogel Cancer Center; Recruiting ➔ Suspended

Clinical • Combination therapy • Trial suspension • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=35; Recruiting; Sponsor: University of Michigan Rogel Cancer Center; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1/2; N=35; Not yet recruiting; Sponsor: University of Michigan Rogel Cancer Center; Phase classification: P2 ➔ P1/2; Trial completion date: Nov 2023 ➔ Apr 2024; Initiation date: Oct 2018 ➔ Apr 2019; Trial primary completion date: Nov 2023 ➔ Apr 2024

Clinical • Combination therapy • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date